Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Crinetics Pharmaceuticals, Inc.

< Previous 1 2 Next >
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.